Reports

Six Month Report of 16 Key Findings

Anabolic Therapy for Combined AA and EDS

 

Supportive Bibliographies

Bibliography in Support of AA Protocol

Bibliography of Articles for Hormone Report

Bibliography of Articles on Neurosteroids

 

Bulletins

Welcome to the Arachnoiditis Bulletins

Bulletin 1 – Explanations and Definitions You Must Know – Revised 3/18

Bulletin 2 – Arachnoiditis No Longer A Rare Disease – Revised 3/18

Bulletin 3 – A Brief History of Arachnoiditis – Revised 10/18

Bulletin 4 – Causes of Arachnoiditis – Revised 10/18

Bulletin 5 – Neuroinflammation is the Root Cause – Revised 10/18

Bulletin 6 – Major Symptoms and Harms of AA – Revised 11/18

Bulletin 7 – Natural Course and Outcome of AA – Revised 11/18

Bulletin 8 – The Diagnosis of AA – Revised 11/18

Bulletin 9 – My Treatment Isn’t Working – Revised 9/18

Bulletin 10 – 10 Component Treatment Protocol – Revised 9/18

Bulletin 11 – Arachnoiditis No Longer Rare

Bulletin 12 – Emergency Treatment for Arachnoiditis

Bulletin 13 – Screening for AA

Bulletin 14 – Ketorolac for AA

Bulletin 15 – Getting Started To Treat and Survive AA

Bulletin 16 – Protocol for Emergency Treatment of Suspected Lumbar-Sacral Arachnoiditis – June 2019

Bulletin 17 – Best Treatment for AA – Revised 3/18

Bulletin 18 – Therapeutic Trials – What are they and why are they essential? – Revised 9/18

Bulletin 19 – Confusion Over Diagnosis of Arachnoiditis – Revised 7/18

Bulletin 20 – Neuroinflammation & Neurodegeneration – Revised 7/18

Bulletin 21 – Self-Help Protocol for Arachnoiditis and Ehlers-Danlos Syndrome

Bulletin 22 – Stem Cells and Electric Stimulators

Bulletin 23 – Most Common Cause of Centralized Intractable Pain (CIP)

Bulletin 24 – Anabolism and Catabolism – You Must Know the Difference

Bulletin 25 – Arachnoiditis Patients Must Have a Compounding Pharmacy